STOCK TITAN

Immunome Inc - IMNM STOCK NEWS

Welcome to our dedicated news page for Immunome (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunome's position in the market.

Rhea-AI Summary
Immunome, Inc. (IMNM) will present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8. The company focuses on developing targeted cancer therapies and invites interested parties to access the live audio webcast from their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
conferences
-
Rhea-AI Summary
Immunome, Inc. (IMNM) and Zentalis Pharmaceuticals, Inc. (ZNTL) have entered into an exclusive, worldwide license agreement for preclinical ROR1 ADC, with ZPC-21 on track for IND submission in 1Q 2025. Immunome will pay $35 million in cash and common stock to Zentalis, with potential milestone payments of up to $275 million and mid-to-high single-digit royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
none
-
Rhea-AI Summary
Immunome, Inc. (IMNM) appoints Phil Roberts as Chief Technical Officer to advance their portfolio of immunotherapies, radioligand therapies, and ADCs towards clinical development. Roberts brings over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
management
Rhea-AI Summary
Immunome, Inc. (IMNM) to present at 42nd Annual J.P. Morgan Healthcare Conference. Clay Siegall, President and CEO, to speak on targeted cancer therapies. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
conferences
-
Rhea-AI Summary
Immunome, Inc. (Nasdaq: IMNM) appoints Carol A. Schafer, a seasoned investment banking and equity capital markets professional, to its Board of Directors. Ms. Schafer brings over 25 years of experience and is currently the Managing Partner of Hyphen Advisors. Her appointment is expected to benefit Immunome's expansion and advancement of targeted oncology therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
management
-
Rhea-AI Summary
Immunome, Inc. (IMNM) Acquires Antibody-Related Assets and Materials from Atreca, Inc. (BCEL)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.73%
Tags
Rhea-AI Summary
IMNM: Immunome to Present at Stifel 2023 Healthcare Conference, CEO Clay Siegall to Speak on Targeted Cancer Therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
conferences
-
Rhea-AI Summary
IMNM - Immunome, Inc. Merger with Morphimmune, $125M Investment, Key Appointments, and Cash Runway Extension. The merger with Morphimmune and $125 million private placement investment aims to accelerate the development of targeted cancer therapies. Dr. Clay B. Siegall appointed as Chairman and CEO, Dr. Bob Lechleider as Chief Medical Officer, and Jean-Jacques Bienaimé as a member of the Board of Directors. Cash runway extended into Q1 2026. Financial results for Q3 2023 reported. Collaboration Revenue with AbbVie at $4 million. R&D and G&A expenses at $4 million each. Net loss at $4 million. Cash and cash equivalents at $91 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Summary
IMNM: Immunome Appoints Jean-Jacques 'JJ' Bienaimé to Board of Directors, an Accomplished Biotech and Pharma Executive with Over 30 Years of Experience, Former CEO of BioMarin Pharmaceuticals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
management
Rhea-AI Summary
Immunome appoints Dr. Bob Lechleider as Chief Medical Officer to advance its pipeline of cancer therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
management
Immunome Inc

Nasdaq:IMNM

IMNM Rankings

IMNM Stock Data

1.23B
44.03M
18.1%
37.51%
5.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bothell

About IMNM

immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.